Host: |
Mouse |
Applications: |
IHC-P |
Reactivity: |
Human |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Mouse monoclonal antibody anti-CD21 (44-196aa) is suitable for use in Immunohistochemistry research applications. |
Clonality: |
Monoclonal |
Clone ID: |
ZM75 |
Conjugation: |
Unconjugated |
Isotype: |
IgG1/Kappa |
Formulation: |
Tris-HCI buffer containing stabilizing protein (BSA) and <0.1% ProClin |
Purification: |
Affinity purified |
Dilution Range: |
1:100‐200 |
Storage Instruction: |
Store at 2‐8°C for up to 24 months. Predilute: Ready to use, no reconstitution necessary. Concentrate: Use dilution range and appropriate lab‐standardized diluent. Stability after dilution: 7 days at 24°C, 3 months at 2‐8°C, 6months at ‐20°C. |
Gene Symbol: |
CR2 |
Gene ID: |
1380 |
Uniprot ID: |
CR2_HUMAN |
Immunogen Region: |
44-196aa |
Specificity: |
Positive control: Tonsil, lymph node |
Immunogen: |
Recombinant human CR2 (CD21) protein fragment (around aa 44-196) |
Tissue Specificity | Mature B-lymphocytes, T-lymphocytes, pharyngeal epithelial cells, astrocytes and follicular dendritic cells of the spleen. |
Function | Receptor for complement C3, for the Epstein-Barr virus on human B-cells and T-cells and for HNRNPU. Participates in B lymphocytes activation. (Microbial infection) Acts as a receptor for Epstein-Barr virus. |
Protein Name | Complement Receptor Type 2Cr2Complement C3d ReceptorEpstein-Barr Virus ReceptorEbv ReceptorCd Antigen Cd21 |
Database Links | Reactome: R-HSA-977606 |
Cellular Localisation | Cell MembraneSingle-Pass Type I Membrane Protein |
Alternative Antibody Names | Anti-Complement Receptor Type 2 antibodyAnti-Cr2 antibodyAnti-Complement C3d Receptor antibodyAnti-Epstein-Barr Virus Receptor antibodyAnti-Ebv Receptor antibodyAnti-Cd Antigen Cd21 antibodyAnti-CR2 antibodyAnti-C3DR antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance